📣 PRESENTING THE CONFIRMED FACULTY OF #ESHAML2027
8th International Conference
AML "Molecular & Translational": Advances in Biology & Treatment
October 4-6, 2027/Estoril, Portugal
Chairs: B. Löwenberg, H. Döhner, B. L. Ebert
For more info ➡ bit.ly/4t46boc
#ESHCONFERENCES #HAEMATOLOGY #LEUsm

Last week's #OncFive:

✅ Pirtobrutinib OK'd in 1L CLL/SLL #lymsm #leusm
🎗️ Priority review: elinzanetant for breast cancer #bcsm
🩸 Tabelecleucel BLA resubmitted in EBV+ PTLD
🫁 Savolitinib+osimertinib NDA in MET+ NSCLC #lcsm
🫁 Zipalertinib NDA starts in NSCLC

🔗: www.onclive.com/view/the-onc...

🚨BREAKING: The @fda.gov has approved pirtobrutinib for adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion #leusm #oncology

Read more: www.onclive.com/view/fda-app...

📰Topline data from the phase 3 portion of the AZTOUND trial showed oral azacitidine and cedazuridine met the pharmacokinetic primary end point in patients with MDS or CMML #mpnsm #leusm #oncology

Read more: www.onclive.com/view/oral-az...

🇨🇳China's NMPA has approved of pirtobrutinib in treatment-naive and previously treated CLL/SLL, based on the phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials.

Full details 💥: onclive.com/view/china-s...

#leusm #oncology

WATCH 👀: Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, of @petermaccc.bsky.social, explains how safety, resistance, and sequencing guide frontline therapy selection in CLL.

Full video ➡️: www.onclive.com/view/dr-ande...

#leusm #oncology #SOHO2026 @societyofhemonc.bsky.social

Bexobrutideg drove responses across treatment lines in CLL/SLL, including in a subgroup of patients with treatment-naive disease. Dive into the #SOHO2026 data here #leusm #oncology www.onclive.com/view/bexobru...

📈 Responses were shown in patients with R/R CLL who had received both a covalent BTK inhibitor and a BCL2 inhibitor, according to a pooled analysis of BRUIN trials.

Read more here ➡️: www.onclive.com/view/pirtobr...

#SOHO2026 #leusm #oncology @societyofhemonc.bsky.social

🤔 Lower risks of TLS were shown for venetoclax-based regimens in patients with CLL compared with MCL, according to a real-world analysis.

Full details 📰: onclive.com/view/venetoc...

#leusm #lymsm #oncology #SOHO2026
@societyofhemonc.bsky.social

Phase 1 data show that dibotatug produced a 60% overall response rate with a favorable safety profile in large granular lymphocytic leukemia. @societyofhemonc.bsky.social #SOHO2026 #leusm #hematology

www.onclive.com/view/dibotat...

The ASC4FIRST trial continued to show higher molecular response rates and better tolerability with asciminib than with standard TKIs in Ph-positive CML. @societyofhemonc.bsky.social #SOHO2026 #leusm #hematology

www.onclive.com/view/ascimin...

Time-limited pirtobrutinib plus venetoclax and obinutuzumab produced high rates of U-MRD in CLL/SLL. #leusm #hematology

See our site for the full story from PIVOT-CLL, as presented by
@nitinjainmd.bsky.social at #SOHO2026! @societyofhemonc.bsky.social

www.onclive.com/view/time-li...

ELVN-001 produced molecular responses in previously treated CP-CML according to updated data from the phase 1 ENABLE trial. @societyofhemonc.bsky.social #leusm #hematology

See our site for the full story, as presented at #SOHO2026! www.onclive.com/view/elvn-00...

📈 The ACTIVE regimen yielded responses in heavily pretreated, relapsed or refractory NPM1-mutated AML, according to findings presented at #SOHO2026. @societyofhemonc.bsky.social #leusm #hematology

See the full story from the retrospective study on our site ➡️: www.onclive.com/view/active-...

Adding revumenib to intensive chemotherapy led to high levels of response and MRD negativity in newly diagnosed AML harboring NPM1 mutations or KMT2A rearrangements #leusm #oncology

Check out the phase 1 data from #SOHO2026 www.onclive.com/view/revumen...

It’s an honor to be captain of Team @roswellpark.bsky.social and a Board of Trustee for @bloodcancerunited.bsky.social
I need your help raising $ for patients, families and critical research for blood cancer. These pennies still matter! #lymsm #mmsm #leusm #bmtsm
pages.lls.org/ltn/wcny/Buf...

2️⃣ conferences at once! Get ready for #SOHO2026 in Houston and #WCLC26 in Seoul!
🤠 Over the next few days, we’ll be covering the two conferences in-depth with expert insight all on our site! 🇰🇷
@societyofhemonc.bsky.social @iaslc.bsky.social #lcsm #leusm #mmsm #mpnsm #lymsm #oncology #hematology

The addition of mipletamig to venetoclax/azacitidine drove clinical benefit in the frontline treatment of patients with AML harboring TP53 mutations #leusm #oncology

Dive into the phase 1b RAINIER data here: www.onclive.com/view/frontli...